MET and non-small cell lung carcinoma: Savolitinib is a selective MET TKI and yielded promising activity in pulmonary sarcomatoid carcinomas and NSCLC with MET exon 14 skipping with ORR reaching 42.9% and an acceptable safety profile (NCT02897479), which has already been approved in China for this kind of NSCLC.211